Although IDH1/2-mutated tumors and those with 1p/19q codeletion are no longer classified as GBM, these findings highlight the potential of CSF for detecting tumor-related DNA alterations and improving differential diagnosis. The gene discussed is IDH1; the disease is neoplasm.